Loading...

DRMA DERMATA THERAPEUTICS INC Management Changes 8-K Filing

DRMT

DRM

DERMATA THERAPEUTICS INC

(DRMA)

2025 8-K

Agreement Termination

Quarterly Financial Update

Stock Offering Update

Dermata Presentation Update

Strategic Shift

Compliance Regained

Quarterly Financial Update

Reverse Stock Split

Reverse Stock Split

Loan Defaults (Secured, Uns...

Clinical Trial Expansion

Delisting due to Non-Compli...

Financial Statements

Warrant Agreement

Acne Treatment Results

Nasdaq Compliance

Private Placement

Earnings Report

Private Placement Fundraising

Filing with Quantitative Data

Increase in Offering Price

Agreement for Stock Sale

Financial Update

Delisting Notice

Entry Into a Material Defin...

Other Special Situation

Delisting Notice

Reverse Stock Split

Quantitative Data

Filing with Quantitative Data

Special Meeting of Stockhol...

Agreement with Existing War...

Filing with Quantitative Data

Quantitative Data

Filing with Quantitative Data

Financial Update

Securities Purchase Agreement

Filing with Quantitative Data

Filing with Quantitative Data

Securities Purchase Agreement

Reverse Stock Split

Filing with Quantitative Data

Special Meeting Approval

External Links:

On June 3, 2025, Dermata Therapeutics, Inc. announced the merger of their accounting firm Moss Adams LLP with Baker Tilly US, LLP, and appointed Baker Tilly as their new independent accountant. Moss Adams' audits for 2024 and 2023 did not contain any adverse opinions or disagreements.

AI Assistant

DERMATA THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.